Tirzepatide is Eli Lilly's GLP-1/GIP dual agonist, sold as Mounjaro for type-2 diabetes and Zepbound for obesity. The Phase 3 SURMOUNT and SURPASS programs established it as the most potent incretin therapy approved.
SURMOUNT-5, the head-to-head against semaglutide, read out in April 2026 with 21.6% mean weight loss at 72 weeks versus 15.4% for semaglutide; 36.2% of tirzepatide patients hit ≥25% weight loss versus 19.4% on semaglutide. The drug also has FDA approval for moderate-to-severe obstructive sleep apnea via the SURMOUNT-OSA program, and Truveta EHR data presented at OMA 2026 reproduced the head-to-head signal in routine 12-month care.
Like semaglutide, tirzepatide sits on the FDA's April 30, 2026 proposal to exclude branded actives from the 503B bulks list. Stories here track new readouts, the head-to-head economics, and the long compounding fight.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.
Eli Lilly confirmed in reporting on June 22-23, 2026 that it is halving its planned €2.3 billion (US$2.7 billion) investment at the under-construction Alzey, Rhineland-Palatinate injectable manufacturing site, reducing planned headcount from approximately 1,000 to 500 and pushing the redirected capital toward US sites, most likely Lilly's Pennsylvania facility. The plant produces injectable GLP-1 drugs Mounjaro (tirzepatide for type-2 diabetes), Zepbound (tirzepatide for obesity), and Trulicity (dulaglutide), and is still scheduled to open in 2027 at the reduced capacity. Lilly cited Germany's proposed healthcare reform legislation, particularly a 'dynamic manufacturer rebate' that would automatically lower drug reimbursements as utilization climbs. Boehringer Ingelheim is also slashing planned German investment by at least $1 billion, and Pfizer CEO Albert Bourla has signaled a reassessment. Lilly's CEO David Ricks told the German government the company 'can no longer commit to the full vision for Alzey.' The cut arrives the same week as STAT's retatrutide compassionate-use story, sharpening the contrast between Lilly's expanding US capital deployment and tightening European pricing.
An analysis of 60,000+ Americans with type 2 diabetes, presented at ENDO 2026 by Sainikhil Sontha (Boston University School of Public Health) and published in the Endocrine Society press release stream, found that 40% of GLP-1 users discontinued the medication within 12 months and roughly 60% had stopped by the end of two years. Among those who stopped, 41.5% restarted within a year and 58% within two years. Discontinuation was higher among Medicaid/Medicare beneficiaries, Black patients, and patients with documented nausea or GI side effects (37% of stoppers). Newer-generation tirzepatide users were 41% less likely to discontinue than liraglutide users, and patients whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. The data complement the Cleveland Clinic 8,000-patient real-world finding (March) and the eClinicalMedicine Budini meta-regression on weight-regain trajectory, sharpening the picture of how GLP-1 therapy churn actually unfolds in US insurance-claims populations.
Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
A real-world comparison of tirzepatide and semaglutide for obesity by Venkatakrishnan and colleagues, published in PNAS Nexus on June 16, reported mean body-weight reductions of 14.7% on tirzepatide versus 10.8% on semaglutide at one year. The tirzepatide arm produced close to twice the proportion of 'high responders' (more than 15% body-weight loss) and lower rates of GI events, headache, and fatigue. Female and white patients responded more strongly on either drug than male, black, or Hispanic patients, who were more frequently in the under-5% weight-loss tier. The findings track with SURMOUNT-5's head-to-head trial result and the April 13 OMA Truveta poster but add a new demographic-disparity dimension that should inform real-world treatment selection.
A Medscape clinical study report June 16 from Federica Vinciguerra and colleagues at the University of Catania documented that tirzepatide reversed post-bariatric-surgery weight regain in patients several years out from sleeve gastrectomy or gastric bypass. Post-surgical weight regain affects roughly 50% of bariatric patients within 2-5 years; until recently, the field had no pharmacologic option that meaningfully reversed it. The Catania data add to the case that GLP-1 incretin therapy is a credible second-line option for the post-surgical regain population, distinct from bariatric revision surgery and the 503A/503B compounded-GLP-1 channel.
The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list enters its final two weeks of public comment on June 15. The 60-day comment window closes June 29, after which the agency will weigh comments and issue final rulemaking. Once finalized, the rule will prohibit 503B outsourcing facilities from bulk-compounding these GLP-1 molecules under any circumstance, including future shortage designation. The 503A pathway through licensed pharmacies remains intact ahead of the July 23-24 PCAC peptide-compounding advisory meeting, but the trajectory for large-scale GLP-1 compounding is fixed. Telehealth platforms (Hims & Hers, LifeMD, others) had already migrated to branded supply via Novo and Lilly partnerships since Q1 2026.
The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.
A study in the International Journal of Obesity compared semaglutide, tirzepatide, and retatrutide in MC4R-knockout mice, a model of the most common monogenic obesity. Over 21 days, mean body-weight reduction reached 31.6% with tirzepatide, 24.1% with retatrutide, and 19.7% with semaglutide, and tirzepatide also suppressed cumulative food intake most aggressively. All three improved plasma insulin, HOMA-IR, cholesterol, and liver-damage markers, suggesting incretin drugs can drive weight loss even when the POMC-MC4R satiety axis is disrupted.
An ECO 2026 analysis covered May 18 by ScienceDaily examined 89,718 patients starting GLP-1 therapy — 75.6% semaglutide, 17.5% tirzepatide, 6.9% liraglutide — and stratified BMI change at year one. In the first year, 27% reduced BMI by less than 5%, 22.4% by 5-10%, 14.1% by 10-15%, and 15.8% by ≥15%, while 20.8% actually gained weight. Greater weight loss correlated with larger reductions in obesity-related risk endpoints; patients who gained weight after starting treatment faced worse health outcomes than untreated comparators in several measures.
The EASO 2026 Nature Medicine framework published May 14, presented at ECO 2026 — formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications with differentiated complication-specific recommendations — has generated initial reception coverage. The Endocrine Society and American Diabetes Association haven't yet issued formal endorsement or counter-response statements as of May 16, though informal commentary from US endocrinologists has been broadly favorable. The framework's main US-specific gap is its silence on cost and insurance access — the algorithm assumes prescribers can choose between semaglutide and tirzepatide based on clinical indication, but US patients without diabetes face the Medicare Part D weight-loss-only exclusion. The Medicare GLP-1 Bridge launching July 1, 2026 partly addresses that gap; broader integration awaits CMS rulemaking. ADA 2026 Scientific Sessions in New Orleans June 5-8 will be the next inflection point for guideline alignment between US and EASO positions.
The Lancet formalized SURMOUNT-MAINTAIN on May 14, 2026, the same day the trial was presented at ECO 2026 in Istanbul. The Phase 3b 112-week study from Dr. Deborah Horn and colleagues at UTHealth Houston re-randomized patients who had reached maximum tolerated dose tirzepatide to continue MTD (15 mg or 10 mg), step down to 5 mg, or switch to placebo. Patients continuing MTD were 7x more likely to maintain their weight loss than those switching to placebo; the 5 mg step-down arm was 4x more likely than placebo. At week 112, MTD continuers preserved all of their initial weight loss; 5 mg-step-down patients lost only 5.6 kg of their initial gains on average. The 'seven times more likely' framing — picked up by EurekAlert and the daily science press — is the cleanest patient-facing summary of maintenance economics published to date.
The European Association for the Study of Obesity published an updated pharmacological framework in Nature Medicine, presented at ECO 2026 in Istanbul on Thursday May 14. Semaglutide and tirzepatide are recommended as first-line treatment for obesity across most complications. Tirzepatide is preferred for obstructive sleep apnea and MASH; semaglutide is preferred for knee osteoarthritis and established cardiovascular disease — and is the only agent with current evidence supporting MASH-fibrosis improvement. The framework integrated evidence through November 21, 2025 from 62 randomized controlled trials. The algorithm uses obesity-related complication presence as the primary treatment-selection factor and provides the first major obesity-society guideline to formally privilege incretin-based therapy across the indication mix.
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
Bloomberg reported May 6 that Eli Lilly's Mounjaro displaced Merck's Keytruda as the world's best-selling pharmaceutical in Q1 2026 — $8.66B Mounjaro Q1 sales vs Keytruda's $7.9B Q1 sales. The Mounjaro+Zepbound combined tirzepatide platform generated $36.5B in 2025, outpacing Keytruda's $31.6B. Keytruda had held the #1 ranking since Q1 2023, when it displaced AbbVie's Humira. The shift is the first time a peptide therapeutic has taken the top spot since the historical run of insulin biosimilars. The narrative also frames Lilly's $4.5B Lebanon Indiana manufacturing recommitment and the broader $21B Indiana capital plan as the supply-chain answer to demand at that scale.
Barclays analyst Emily Field raised her price target on Eli Lilly to $1,400 from $1,350 May 5 and reiterated an Overweight rating, citing tirzepatide momentum continuing to outpace the GLP-1 class and easing concerns around the Foundayo launch trajectory. LLY stock had recovered roughly 11% off the May 4 Foundayo FAERS-driven dip to about $966 by mid-week. Barclays simultaneously trimmed its 2026 Foundayo revenue estimate to approximately $1B (vs. ~$1.4B consensus) on the early IQVIA gap to Wegovy pill, but the higher headline target reflects confidence that Mounjaro and Zepbound's volume growth more than absorbs Foundayo's slower start.
Eli Lilly stock has gained roughly 11% over the past week, recovering from the May 4 Foundayo hepatic-failure FAERS report-driven 3% premarket dip and consolidating gains from the April 30 Q1 beat. Per the May 6 analyst consensus across 19 covering firms, LLY now carries an average 12-month price target of $1,228 — implying 24.15% upside from current $966 — with a Buy consensus rating. The recovery framework: tirzepatide volume (+125% global Q1 growth) anchors the floor, retatrutide TRIUMPH program (seven Phase 3 readouts due in 2026) anchors the upside, the small-molecule manufacturing economics of Foundayo offset peptide CDMO bottlenecks, and Pfizer's MariTide/MET-097i and Novo's CagriSema higher-dose program don't read out until 2027.